Sarah C Markt1, Carlos A Lago-Hernandez2, Rowan E Miller2, Brandon A Mahal2, Brandon Bernard2, Laurence Albiges2, Lindsay A Frazier3, Clair J Beard4, Alexi A Wright5, Christopher J Sweeney6. 1. Department of Epidemiology, Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 2. Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts. 3. Dana-Farber Children's Cancer Center, Boston, Massachusetts. 4. Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts. 5. Department of Medical Oncology and Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts. 6. Lank Center for Genitourinary Oncology, Department of Medical Oncology, Dana-Farber/Brigham and Women's Cancer Center, Boston, Massachusetts. christopher_sweeney@dfci.harvard.edu.
Abstract
BACKGROUND: People aged 26 to 34 years represent the greatest proportion of the uninsured, and they have the highest incidence of testicular cancers. The aim of this study was to investigate the association between insurance status and cancer outcomes in men diagnosed with germ cell tumors. METHODS: The Surveillance, Epidemiology, and End Results database was used to identify 10,211 men diagnosed with germ cell gonadal neoplasms from 2007 to 2011. Associations between insurance status and characteristics at diagnosis and receipt of treatment were examined with log-binomial regression. The association between insurance status and mortality was assessed with Cox proportional hazards regression. RESULTS: Uninsured patients had an increased risk of metastatic disease at diagnosis (relative risk [RR], 1.26; 95% confidence interval [CI], 1.15-1.38) in comparison with insured patients, as did Medicaid patients (RR, 1.62; 95% CI, 1.51-1.74). Among men with metastatic disease, uninsured and Medicaid patients were more likely to be diagnosed with intermediate/poor-risk disease (RR for uninsured patients, 1.22; 95% CI, 1.04-1.44; RR for Medicaid patients, 1.39; 95% CI, 1.23-1.57) and were less likely to undergo lymph node dissection (RR for uninsured patients, 0.74; 95% CI, 0.57-0.94; RR for Medicaid patients, 0.76; 95% CI, 0.63-0.92) in comparison with insured patients. Men without insurance were more likely to die of their disease (hazard ratio [HR], 1.88; 95% CI, 1.29-2.75) in comparison with insured men, as were those with Medicaid (HR, 1.51; 95% CI, 1.08-2.10). CONCLUSIONS: Patients without insurance and patients with Medicaid have an increased risk of presenting with advanced disease and dying of the disease in comparison with those who have insurance. Future studies should examine whether implementation of the Patient Protection and Affordable Care Act reduces these disparities. Cancer 2016;122:3127-35.
BACKGROUND:People aged 26 to 34 years represent the greatest proportion of the uninsured, and they have the highest incidence of testicular cancers. The aim of this study was to investigate the association between insurance status and cancer outcomes in men diagnosed with germ cell tumors. METHODS: The Surveillance, Epidemiology, and End Results database was used to identify 10,211 men diagnosed with germ cell gonadal neoplasms from 2007 to 2011. Associations between insurance status and characteristics at diagnosis and receipt of treatment were examined with log-binomial regression. The association between insurance status and mortality was assessed with Cox proportional hazards regression. RESULTS: Uninsured patients had an increased risk of metastatic disease at diagnosis (relative risk [RR], 1.26; 95% confidence interval [CI], 1.15-1.38) in comparison with insured patients, as did Medicaid patients (RR, 1.62; 95% CI, 1.51-1.74). Among men with metastatic disease, uninsured and Medicaid patients were more likely to be diagnosed with intermediate/poor-risk disease (RR for uninsured patients, 1.22; 95% CI, 1.04-1.44; RR for Medicaid patients, 1.39; 95% CI, 1.23-1.57) and were less likely to undergo lymph node dissection (RR for uninsured patients, 0.74; 95% CI, 0.57-0.94; RR for Medicaid patients, 0.76; 95% CI, 0.63-0.92) in comparison with insured patients. Men without insurance were more likely to die of their disease (hazard ratio [HR], 1.88; 95% CI, 1.29-2.75) in comparison with insured men, as were those with Medicaid (HR, 1.51; 95% CI, 1.08-2.10). CONCLUSIONS:Patients without insurance and patients with Medicaid have an increased risk of presenting with advanced disease and dying of the disease in comparison with those who have insurance. Future studies should examine whether implementation of the Patient Protection and Affordable Care Act reduces these disparities. Cancer 2016;122:3127-35.
Authors: Blase N Polite; Jennifer J Griggs; Beverly Moy; Christopher Lathan; Nefertiti C duPont; Gina Villani; Sandra L Wong; Michael T Halpern Journal: J Clin Oncol Date: 2014-11-17 Impact factor: 44.544
Authors: Phillip J Gray; Chun Chieh Lin; Helmneh Sineshaw; Jonathan J Paly; Ahmedin Jemal; Jason A Efstathiou Journal: Cancer Date: 2014-10-24 Impact factor: 6.860
Authors: Ayal A Aizer; Benjamin Falit; Mallika L Mendu; Ming-Hui Chen; Toni K Choueiri; Karen E Hoffman; Jim C Hu; Neil E Martin; Quoc-Dien Trinh; Brian M Alexander; Paul L Nguyen Journal: J Clin Oncol Date: 2014-06-02 Impact factor: 44.544
Authors: Michael Padgett; Shivam M Kharod; Catherine E Mercado; Christopher G Morris; Michael S Rutenberg; Romaine C Nichols Journal: J Gastrointest Oncol Date: 2022-06
Authors: Walter Hsiang; Xuesong Han; Ahmedin Jemal; Kevin A Nguyen; Brian Shuch; Henry Park; James B Yu; Cary P Gross; Amy J Davidoff; Michael S Leapman Journal: Urol Pract Date: 2020-07-01
Authors: Daniel R Evans; Alexander L Lazarides; Mark M Cullen; Jason A Somarelli; Dan G Blazer; Julia D Visguass; Brian E Brigman; William C Eward Journal: Ann Surg Oncol Date: 2021-09-27 Impact factor: 5.344
Authors: John Michael Varlotto; Richard Voland; Kerrie McKie; John C Flickinger; Malcolm M DeCamp; Debra Maddox; Paul Rava; Thomas J Fitzgerald; Geoffrey Graeber; Negar Rassaei; Paulo Oliveira; Suhail Ali; Chandra Belani; Jonathan Glanzman; Heather A Wakelee; Manali Patel; Jennifer Baima; Jianying Zhang; William Walsh Journal: Cancer Med Date: 2018-03-13 Impact factor: 4.452
Authors: Jie Lin; Julie A Bytnar; Brett J Theeler; Katherine A McGlynn; Craig D Shriver; Kangmin Zhu Journal: Cancer Date: 2020-04-14 Impact factor: 6.921
Authors: Henry W Young; Emmett T Martin; Evan Kwiatkowski; J Adrian Tyndall; Linda B Cottler Journal: Emerg Med Int Date: 2020-06-29 Impact factor: 1.112